Oxford Global Conferences Ltd are proud to present the 9th Annual Biomarkers Congress 2014, taking place on 25 & 26 February 2014 in Manchester, United Kingdom.
The increasing interest in biomarker discovery in recent years has pushed biomarker research into the foreground of the modern pharmaceutical industry. New identification technologies have both widened the scope of biomarker research and underlined the need for robust validation, improved predictive value and the clear demonstration of clinical relevance.
The Biomarkers Congress will cover the latest advances in biomarker discovery and verification, including mass cytometry, selected reaction monitoring and chemical genetics.
Our expert speakers will also discuss efforts to increase biomarker sensitivity and specificity through genomic analysis, informatics approaches and better sample management. In the Companion Diagnostics stream, presentations will cover emerging technologies, optimisation of existing platforms and strategies to improve strategic partnerships.
To build on the clinical case studies shared at last year’s event, we are pleased to introduce the co-located “Biomarkers in Clinical Development Congress”, focusing on the role of biomarkers in clinical decision making, drug efficacy prediction and clinical safety. Key decision makers in personalised medicine will complement these discussions with their insights into pharmacogenomics, stratification markers and precision medicine.
Congress Topics
In keeping with Oxford Global’s highly successful life sciences series, an expert panel of over 50 speakers will present a full conference programme covering the topics outlined below:
Biomarkers In Discovery & Preclinical Development
(Day 1 Stream 1)
- Safety biomarkers: validation and regulation
- Biomarker research: key learnings from preclinical models and experimental medicine
- PK/PD studies: predictive science from a biomarker perspective
- Imaging biomarkers: new technologies
- Biomarker outsourcing strategies
- Capturing real-world data in biomarker research
Companion Diagnostics
(Day 1 Stream 2)
- How best to mature emerging technologies into companion diagnostics
- Companion diagnostics in cancer drug development
- Human tissue collection in diagnostics research
- Strategic partnership best practice in companion diagnostics development
- Optimising targets and platforms for the development of biomedical diagnostics
Biomarker Discovery & Verification
(Day 2 Stream 1)
- Biomarker analysis: technologies & platforms
- Development and validation of challenging biomarker assays
- Applications of selected reaction monitoring in pharma
- Informatics in biomarker discovery
- Mass cytometry: a promising novel technology for biomarker discovery
- Big data innovation in biomarker research
- The role of biobanking in biomarker research
Innovations In Biomarker Research
(Day 2 Stream 2)
- Collaborative strategies: building on the success of safety biomarker initiatives
- Latest updates from correlative science teams
- New advances in circulation tumour cell research
- Novel biomarker identification methods: exploiting structure and chemical genetics
- Innovation case studies: oncology and respiratory biomarkers
Biomarkers In Clinical Development Congress
Clinical Biomarkers
(Day 1)
- Biomarker development and clinical application
- Biomarker research: a clinician’s perspective
- Translating biomarkers into clinical assays
- Clinical genetics: developing diagnostic assays with clinical utility
- Fit for purpose development of clinical biomarkers
- Successful clinical validation of biomarkers
Clinical Trials & Personalised Medicine
(Day 2)
- Advancing personalised medicine: case studies from clinical teams
- Personalised medicine and pharmacogenomics: the generic company’s perspective
- Finding the right patient population: mining clinical study data
- Precision medicine: updates from large pharma
- Developing patient selection markers
- Identifying the right patient for targeted therapy
Who will attend
The 9th Annual Biomarkers Congress is an exclusive event designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions.
Delegates typically include VPs, Directors and Global Heads of:
- Adaptive trial design
- Assay development
- Assay validation
- Biobanking
- Bioinformatics
- Biomarker development
- Biomarker identification
- Biomarker validation
- Biomarker discovery
- Clinical safety
- Companion diagnostics
- Immunoassays
- Patient stratification
- Personalised medicine
- Pharmacogenomics
- PK/PD
- Precision medicine
- Rx/Dx co-development
Submit a Poster
For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.
We will require:
- Poster title, Abstract (200 words or less)
- Principal author, Organisation, Mailing address, Email, Telephone, Fax
- Additional authors
In order to secure your board space a fee of £125 will be required.
To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available, so please register soon!
Advisory Board
Our 2014 Advisory Board includes
- Corinne Solier – Group Head, Clinical Protein Biomarkers, Roche
- Terry Robins – Director, Biomarker Research and Development & Global Scientific Affairs, Quest Diagnostics
- John Allinson – VP Biomarker Lab Services, Icon
- Khusru Asadullah – VP and Head of Global Biomarker, Bayer Health Care
- Stephen Roy Pennington – Professor of Proteomics, University College Dublin
- Alain Van Gool, Professor – Senior Scientist Integrator Metabolic Health Research, TNO